The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase 2 trial in progress of flexible and extended dosing of 177Lu-PSMA-617 molecular radioligand therapy in mCRPC (FLEX-MRT).
 
Adrien Holzgreve
Consulting or Advisory Role - ABX Advanced biochemical compounds
 
Astrid Delker
No Relationships to Disclose
 
Zachary Ells
No Relationships to Disclose
 
Julia Brosch-Lenz
No Relationships to Disclose
 
Shaojun Zhu
No Relationships to Disclose
 
Stephanie Lira
No Relationships to Disclose
 
John Nikitas
No Relationships to Disclose
 
Tristan Grogan
No Relationships to Disclose
 
David Elashoff
No Relationships to Disclose
 
Lena M. Unterrainer
No Relationships to Disclose
 
Magnus Dahlbom
No Relationships to Disclose
 
Martin S. Allen-Auerbach
No Relationships to Disclose
 
Johannes Czernin
Leadership - SOFIE; Trethera
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Advanced Accelerator Applications; Aktis Oncology; Amgen; Jubilant Radiopharma; POINT Biopharma; RayzeBio
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics